Activity of minocycline against Klebsiella pneumoniae carbapenemase (KPC)-producing Enterobacteriaceae clinical isolates, with comparison to doxycycline and tigecycline

Abstract We examined the in vitro activity of minocycline against 103 Klebsiella pneumoniae carbapenemase (KPC)-producing Enterobacteriaceae isolates and found approximately half had susceptible (26%) or intermediate (26%) MICs. For a subset of 35 isolates, susceptibility was highest to tigecycline...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Diagnostic microbiology and infectious disease 2017-08, Vol.88 (4), p.365-367
Hauptverfasser:	Chen, Alice, Smith, Kenneth P, Whitfield, Betsy A, Zucchi, Paola C, Lasco, Todd M, Bias, Tiffany E, Kirby, James E, Hirsch, Elizabeth B
Format:	Artikel
Sprache:	eng
Schlagworte:	Anti-Bacterial Agents - therapeutic use Bacterial Proteins - metabolism beta-Lactamases - metabolism Carbapenem-Resistant Enterobacteriaceae - drug effects Carbapenem-Resistant Enterobacteriaceae - metabolism Doxycycline - therapeutic use Enterobacteriaceae Infections - drug therapy Enterobacteriaceae Infections - microbiology Extended-spectrum beta-lactamase Humans Infectious Disease Internal Medicine Klebsiella pneumoniae - drug effects Klebsiella pneumoniae - metabolism KPC Microbial Sensitivity Tests Minocycline - analogs & derivatives Minocycline - therapeutic use Multidrug resistance Resistant Tetracycline
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Abstract We examined the in vitro activity of minocycline against 103 Klebsiella pneumoniae carbapenemase (KPC)-producing Enterobacteriaceae isolates and found approximately half had susceptible (26%) or intermediate (26%) MICs. For a subset of 35 isolates, susceptibility was highest to tigecycline (71% FDA vs. 20% EUCAST) followed by minocycline (14%) and then doxycycline (6%).
ISSN:	0732-8893 1879-0070
DOI:	10.1016/j.diagmicrobio.2017.05.004